 OPKO Health Inc NASDAQ: OPK reported Q3 revenues were down 10 YY to 385.8 million, beating the consensus of 302.27 million. Revenue from diagnostic services decreased to 340.1 million from 382.5 million, primarily due to a decrease in COVID-19 testing volume, partially offset by an improvement in COVID-19 test reimbursement and an increase in clinical and genomic test revenue. 